Quanterix sNfL Assay and Simoa Technology First to Measure Neuronal Injury in COVID-19 Patients’ Blood

July 29, 2020 at 9:30 AM EDT

Findings offer first-time evidence of neuro-axonal damage in mild-to-moderate cases of SARS-CoV-2 and validate serum neurofilament light chain (sNfL) as a highly specific biomarker to measure and monitor damage during and post infection

BILLERICA, Mass.--(BUSINESS WIRE)--Jul. 29, 2020-- Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced that quantitative testing using its sNfL Assay and Simoa® technology was used to show that COVID-19 may affect the neurological integrity of adult patients who experience a mild-to-moderate form of the virus. Published in the Journal of Neurology, the study offers new evidence of SARS-CoV-2’s neuro-destructive capabilities as it relates to less severe cases. These results support the utility of sNfL as a screening and monitoring tool for measuring neuronal injury throughout COVID-19 disease progression and recovery, as well as lays the foundation for the evaluation of potential long-term neurological impact following COVID-19 recovery.

While COVID-19 manifests predominantly as a respiratory illness, numerous accounts and preliminary research studies connect the virus to multiple neurological conditions, including headache, stroke, cognitive loss, anosmia (loss of smell) and ageusia (loss of taste). This body of evidence demonstrating the virus’s impact on the nervous system continues to grow, most recently with research in Brain linking COVID-19 to delirium, brain inflammation, stroke and nerve damage. However, experts caution that it could require years of study to fully understand the long-term effects of these symptoms.

“It’s becoming alarmingly clear just how much we still do not understand about COVID-19 and how our testing regimen needs to improve in accuracy and precision,” said Kevin Hrusovsky, Chairman, Chief Executive Officer and President, Quanterix and Founder, Powering Precision Health (PPH). “Harnessing the power of biomarkers to shed light on these scientific mysteries and improve testing precision is the collective missions at Quanterix and PPH. We’re compelled to work closely with researchers across our global syndicate to apply our breadth of expertise and technologies – as generated by hundreds of studies across Alzheimer’s disease, Parkinson’s disease, Multiple Sclerosis (MS) and other neurological conditions – to understanding the short and long-term neurological impacts of COVID-19. This study represents a significant step toward this goal because it provides novel data on the virus’s neuro-axonal impact and validates a key means of studying it through sNfL, which will be critical to public health in the years ahead.”

Conducted by a team of researchers from the University Children’s Hospital Regensburg (KUNO) and the University Hospital Basel in Switzerland, the study analyzed a cohort of 100 healthcare workers without known co-morbidities, composed of 84 females and 16 males, following a COVID-19 outbreak at a major hospital in Germany. Subjects were stratified by infection status and age, and their sNfL concentrations were measured approximately 23 days after disease onset and again approximately 35 days later using the Simoa NF-light ® kit on the Simoa HD-X AnalyzerTM. Notably, all positive patients reported mild-to-moderate symptoms with recovery within one-to-three weeks and showed no or only minor neurological symptoms.

Results revealed that COVID-19 status was significantly associated with sNfL when controlling for age and gender. In patients with two sNfL measurements, sNfL levels were highly correlated. As NfL is a well-established marker for neuronal damage, elevated levels in serum suggest acute or chronic neuro-axonal damage as a result of COVID-19, even in mild or moderate forms.

“We’re proud to share this paper with the scientific community at-large, as we believe it offers important insight into neurological ramifications among a cohort that represents the vast majority of COVID-19 cases,” said Jens Kuhle, MD, professor at University of Basel and a lead researcher on the study. “Preliminary research conducted early on in the pandemic mainly assessed hospitalized, and therefore, the most severe patients’ neurological response. In contrast, our study evaluated the virus’s neuron-destructive capabilities in instances where patients experienced mild to no symptoms and had no known co-morbidities that could exacerbate neurological declines. The ability to not only see but also accurately quantify NfL through an easily administered blood test using the ultra-sensitive Simoa platform was instrumental to the success of this project, and we believe it will also be important to the feasibility of long-term studies.”

“It’s incredible to see members of the PPH network continuing to bring seminal research to light,” continued Hrusovsky. “This information is indispensable as we face a resurgence of the virus and medical supply shortages in numerous cities across the globe. Looking ahead, the ability to see indicators of COVID-19’s effects in blood creates the potential for regular screenings at clinics or via homecare sampling to validate these and other important findings on a larger scale. Expanding research through those pathways will also be vital to guiding therapeutic development, assessing the efficacy of vaccines and informing patient care decisions as we continue to learn more about the virus.”

The PPH network is working to solidify several important forums over the coming months that will encompass multiple therapeutic areas including COVID-19, neurology, public health policy and their intriguing intersection.

Further details on Quanterix’ infectious disease offerings and educational resources, can be accessed here: https://www.quanterix.com/therapeutic-areas/infectious-disease.

For more information on CLIA-certified Accelerator Lab services, visit: https://www.quanterix.com/simoa-accelerator-laboratory.

Details on the company’s homebrew services for developing customer Simoa assays are available here: https://www.quanterix.com/products-technology/homebrew.

COVID-19 investigators with questions about Simoa or who are in need of testing support are encouraged to contact our team at: https://www.quanterix.com/contact.

For more details on PPH, visit: https://www.poweringprecisionhealth.org

About Quanterix 

Quanterix is a company that’s digitizing biomarker analysis with the goal of advancing the science of precision health. The company’s digital health solution, Simoa, has the potential to change the way in which healthcare is provided today by giving researchers the ability to closely examine the continuum from health to disease. Quanterix’ technology is designed to enable much earlier disease detection, better prognoses and enhanced treatment methods to improve the quality of life and longevity of the population for generations to come. The technology is currently being used for research applications in several therapeutic areas, including oncology, neurology, cardiology, inflammation and infectious disease. The company was established in 2007 and is located in Billerica, Massachusetts. For additional information, please visit https://www.quanterix.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate," "estimate," "intend" and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements in this news release are based on Quanterix’ expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Factors that may cause Quanterix’ actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Quanterix’ filings with the U.S. Securities and Exchange Commission, including the "Risk Factors" sections contained therein. Except as required by law, Quanterix assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.

Media Contact:
PAN Communications
Staci Didner, (407) 734-7325
quanterix@pancomm.com

Investor Relations Contact:
Stephen Hrusovsky
(774) 278-0496
shrusovsky@quanterix.com

Source: Quanterix Corporation